A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis. The researchers have identified new biomarkers for Tuberculosis (TB) which have shown for the first time why immunity from the widely used Bacillus Calmette-Guérin (BCG) vaccine is so variable. The biomarkers will also provide valuable clues to assess whether potential new vaccines could be effective.
Aeras and the Human Vaccines Project announced a new collaboration aimed at accelerating the development of vaccines and immunotherapies for key global populations. The Human Vaccines Project is a new global initiative that brings together leading academic centers, industry, nonprofits and governments in a global discovery consortium to solve the primary scientific hurdles impeding the development of vaccines and immune-driven therapies.
Aeras, a non-profit biotechnology organization developing new tuberculosis (TB) vaccines for the world, is launching a new 90-second animated video in honor of World TB Day to help raise awareness about TB’s devastating toll and the need for new tools, including vaccines, to fight this epidemic. In its latest annual report on TB, the World Health Organization (WHO) revealed that the epidemic caused 9.6 million illnesses and 1.5 million deaths in 2014.
Aeras today announced that Danilo Casimiro, Ph.D., has joined the organization as Chief Scientific Officer (CSO) effective February 29. Dr. Casimiro joins Aeras from the Merck Research Laboratories, where he was Executive Director in the Department of Infectious Diseases and Vaccine Research.
The White House plan to address drug-resistant tuberculosis (TB), The National Action Plan for Combating Multidrug-Resistant Tuberculosis, released today, is an important step in the U.S. government’s response to this deadly infectious disease.